全文获取类型
收费全文 | 2104篇 |
免费 | 102篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 20篇 |
妇产科学 | 51篇 |
基础医学 | 186篇 |
口腔科学 | 5篇 |
临床医学 | 135篇 |
内科学 | 338篇 |
皮肤病学 | 12篇 |
神经病学 | 295篇 |
特种医学 | 9篇 |
外科学 | 154篇 |
综合类 | 64篇 |
预防医学 | 27篇 |
眼科学 | 14篇 |
药学 | 884篇 |
中国医学 | 3篇 |
肿瘤学 | 27篇 |
出版年
2024年 | 5篇 |
2023年 | 40篇 |
2022年 | 45篇 |
2021年 | 46篇 |
2020年 | 74篇 |
2019年 | 67篇 |
2018年 | 55篇 |
2017年 | 60篇 |
2016年 | 67篇 |
2015年 | 57篇 |
2014年 | 82篇 |
2013年 | 230篇 |
2012年 | 52篇 |
2011年 | 64篇 |
2010年 | 50篇 |
2009年 | 73篇 |
2008年 | 68篇 |
2007年 | 62篇 |
2006年 | 52篇 |
2005年 | 48篇 |
2004年 | 55篇 |
2003年 | 54篇 |
2002年 | 47篇 |
2001年 | 27篇 |
2000年 | 40篇 |
1999年 | 19篇 |
1998年 | 34篇 |
1997年 | 38篇 |
1996年 | 33篇 |
1995年 | 40篇 |
1994年 | 29篇 |
1993年 | 28篇 |
1992年 | 37篇 |
1991年 | 40篇 |
1990年 | 43篇 |
1989年 | 33篇 |
1988年 | 29篇 |
1987年 | 21篇 |
1986年 | 17篇 |
1985年 | 38篇 |
1984年 | 47篇 |
1983年 | 32篇 |
1982年 | 49篇 |
1981年 | 23篇 |
1980年 | 27篇 |
1979年 | 15篇 |
1978年 | 9篇 |
1977年 | 5篇 |
1976年 | 13篇 |
1975年 | 9篇 |
排序方式: 共有2232条查询结果,搜索用时 46 毫秒
1.
Alessandro Vatrella Angelantonio Maglio Corrado Pelaia Girolamo Pelaia Carolina Vitale 《Expert opinion on pharmacotherapy》2020,21(12):1505-1515
ABSTRACT
Introduction
‘Critical Asthma Syndrome’ (CAS) is an umbrella term proposed to include several forms of asthma, responsible for acute and life-threatening exacerbations. CAS requires urgent and adequate supportive and pharmacological treatments to prevent serious outcomes. 相似文献2.
3.
4.
Activity at 5-HT1 and 5-HT2 receptor sites influences sexual behavior in male and female rats. 5-HT3 antagonists reportedly have no effect on copulatory activity in rats of either sex although they influence a variety of other behaviors. The effects of 5-HT3 agonists on sexual behavior are unknown. The following experiments were undertaken to assess the influence of the 5-HT3 agonists 1-phenylbiguanide (PBG) and 2-methyl-serotonin (2-Me-5-HT) on sexual behavior, when administered intracerebroventricularly. Consistent with earlier reports indicating that 5-HT1 and 5-HT2 receptor activity influences reproductive activity in a sex-dependent manner, PBG was found to facilitate male, but not female, rat sexual behavior. 2-Me-5-HT, however, failed to modify either female or male rat sexual activity. Evidence that PBG, but not 2-Me-5-HT, induces carrier-mediated dopamine release suggests that the effect of PBG in male rats is due to dopaminergic mediation. Overall, the present data indicate that 5-HT3 receptor activation has only slight effects on rat sexual behavior. 相似文献
5.
Martine Hascoët Michel Bourin Jacques Bradwejn 《Progress in neuro-psychopharmacology & biological psychiatry》1991,15(6):825-840
1. The mechanism of action of drugs might change according to the test used. Several noradrenergic drugs were tested in order to understand their implication in the mobility tests.
2. It was found that clonidine, an Alpha 2 agonist, acted differently according to the tast used. It provoked sedation in spontaneous activity test, and anti-immobility effects in the other tests.
3. Tall suspension test is able to show the double acting of clonidine.
4. Idazoxan might act either as an alpha 2 antagonist or as partial alpha 2 agonist. TST shown the unexpected partial alpha agonist effect of the molecule.
5. Forced swimming test is more specific for predicting antidepressant activity than tail suspension test which is close to a spontaneous activity model. 相似文献
6.
7.
In this study, the behavioural response to dopamine D1-like receptor agonists (SKF 38393, SKF 81297 and SKF 77434) and D2-like receptor agonists (quinpirole and RU 24213), administered alone and in combination to rats treated repeatedly with electroconvulsive
shock (five ECS over 10 days) or sham, was tested. Agonist-induced behaviour was monitored by automated activity meters and
direct observation using a checklist scoring method. Repeated ECS (compared to sham controls) had no significant effect on
the behavioural response to SKF 38393 (7.5 mg/kg SC), SKF 81297 (0.2 mg/kg SC), SKF 77434 (0.1 mg/kg SC), quinpirole (0.1
and 0.25 mg/kg SC) or RU 24213 (0.3 mg/kg SC), when administered alone. In contrast, repeated ECS markedly increased locomotion
(activity counts and scores) induced by the non-selective dopamine agonist apomorphine (0.5 mg/kg SC) and by co-administration
of a D1-like agonist plus a D2-like agonist [SKF 38393 (7.5 mg/kg SC) plus quinpirole (0.25 mg/kg SC), SKF 81297 (0.2 mg/kg SC) plus quinpirole (0.1 mg/kg
SC), and SKF 77434 (0.1 mg/ kg SC) plus RU 24213 (0.3 mg/kg SC)]. This ECS-induced enhancement of dopamine-mediated behaviour
was observed for up to 3 weeks after cessation of ECS treatment. In addition, ECS also enhanced the locomotor response to
intra-accumbens SKF 38393 plus quinpirole (0.4 and 1.0 μg/side, respectively). These results provide evidence that the enhancement
of dopamine function by repeated ECS requires concomitant stimulation of both D1-like and D2-like receptors, and that this effect is long-lasting.
Received: 24 January 1997 /Final version: 5 March 1997 相似文献
8.
Summary. Platelet membranes provide procoagulant surfaces for the assembly and expression of the factor X-activating complex and promote the proteolytic activation and assembly of the prothrombinase complex resulting in normal hemostasis. Recent studies from our laboratory and others indicate that platelets possess specific, high-affinity, saturable, receptors for factors XI, XIa, IX, IXa, X, VIII, VIIIa, V, Va and Xa, prothrombin, and thrombin. Studies described in this review support the hypothesis that the factor X-activating complex on the platelet surface consists of three receptors (for the enzyme, factor IXa; the substrate, factor X; and the cofactor, factor VIIIa), the colocalization of which results in a 24 million-fold acceleration of the rate of factor X activation. Whether the procoagulant surface of platelets is defined exclusively by procoagulant phospholipids, or whether specific protein receptors exist for the coagulant factors and proteases, is currently unresolved. The interaction between coagulation proteins and platelets is critical to the maintenance of normal hemostasis and is pathogenetically important in human disease. 相似文献
9.
G. D'Agostino M. C. Chiari E. Grana 《Naunyn-Schmiedeberg's archives of pharmacology》1989,340(1):76-81
Summary The inhibitory effects of some muscarinic agonists on tritiated acetylcholine release evoked by field stimulation were investigated in the rat urinary bladder strip. The acetylcholine stores of the preparation were labelled with 3H-choline. Electrical field stimulation caused an outflow of tritium, reflecting the release of 3H-acetylcholine. The release of 3H-acetylcholine was decreased in a concentration-dependent manner by all the agonists tested: oxotremorine, muscarone, muscarine, carbachol and methylfurtrethonium. On the contrary, only muscarine and muscarone enhanced the basal efflux of tritium in a concentration-dependent fashion. Concentration-response curves were determined both at 2 Hz and at 1 Hz by using intermittent administration of the drugs. Maximal depression in release (by 78 – 82%) was observed in experiments at 1 Hz. A similar inhibition was obtained at 2 Hz frequency only when a low concentration of calcium (0.6 mM) in the medium was used. Oxotremorine was the most potent among the tested compounds with the same intrinsic activity as the other drugs. In contrast to the other agonists investigated, oxotremorine showed in about 10-fold greater potency at pre- than at postjunctional muscarine receptors in the rat urinary bladder. This difference might depend either on heterogeneity of muscarine receptors or on different mechanism(s) relating to the transducing properties of receptors at the pre- and postjunctional level. A comparison between the relative prejunctional potencies in the rat urinary bladder and in the guinea pig myenteric plexus (data from the literature) suggests that prejunctional muscarine receptors are similar in these tissues. Furthermore, the findings obtained with a low concentration of calcium in the medium may support the view that intraneuronal availability of calcium plays a significant role in modulating the prejunctional negative feed-back mechanism in the rat urinary bladder.Send offprint requests to Dr. G. D'Agostino at the above address 相似文献
10.
Alexandre Castro-Caldas Paul Delwaide Wolfgang Jost Marcelo Merello Adrian Williams Paolo Lamberti Miguel Aguilar Susanna Del Signore Pierre Cesaro 《Movement disorders》2006,21(4):500-509
Dopamine agonists have been recommended as early treatment for Parkinson's disease (PD), alone or combined with levodopa. Piribedil is a non-ergot selective D(2)/D(3) agonist with alpha(2) antagonist properties shown to be effective in the treatment of PD. This 12-month international, randomized, double-blind trial aimed to assess the efficacy of piribedil 150 mg versus bromocriptine 25 mg, in early combination with levodopa in Stage I to III PD patients. Motor efficacy was assessed using the Unified Parkinson's Disease Rating Scale (UPDRS III, Items 18-31) as improvement from baseline. Response rate was defined as a 30% improvement. Among the 425 randomly assigned patients, 178 were also included in a substudy on cognitive follow-up evaluated by a dysexecutive syndrome oriented battery. A relevant improvement in UPDRS III over the 12-month study duration was observed both in the piribedil and bromocriptine groups (-7.9 +/- 9.7 points from baseline versus -8.0 +/- 9.5; not significant [n.s.]) with a response rate of 58.4% and 55.3% (n.s.), respectively. Piribedil and bromocriptine resulted in similar improvement on all UPDRS III subscores. Piribedil patients required less levodopa dose increase than those on bromocriptine. Cognitive performance remained generally unchanged in both groups, with a significant effect of piribedil limited to the Wisconsin Card Sorting Test. An overall good tolerability of piribedil was observed. Early combination of piribedil 150 mg with levodopa resulted in significant long-term improvement of all motor symptoms in PD patients insufficiently controlled by levodopa alone. Taking into account both efficacy and acceptability in the long-term, piribedil proved in this bromocriptine controlled study to be an effective and safe treatment for PD. 相似文献